Αρχική World News Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS in... World News Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer Από Ogkologos - 15 Νοεμβρίου, 2024 759 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COMPASSION-16 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial... 22 Νοεμβρίου, 2022 Patient Guide in Colorectal Cancer Now Available in Bulgarian 18 Φεβρουαρίου, 2026 Researchers Have Discovered How Fat Cells Fuel The Spread Of Breast... 19 Δεκεμβρίου, 2019 Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 26 Φεβρουαρίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Cancer in My Community: Overcoming Delays in Care for Children With... ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ ΑΔΕΝΑ ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ Los ensayos clínicos y las personas mayores, con Dr. Enrique Soto